Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 13/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403137 | 0.93 | LMNA (0.48) | CASRALDH1A1LMNAMAPTCHRM2 | |
| SCHEMBL4401060 | 0.92 | CASR (0.47) | CASRALDH1A1LMNAMAPT | |
| SCHEMBL4393898 | 0.91 | CASR (0.45) | CASRALDH1A1LMNAMAPTCHRM2 | |
| SCHEMBL4389884 | 0.91 | MAPT (0.48) | CASRCCR5MAPTCHRM2CHRM4 | |
| SCHEMBL4393902 | 0.87 | CASR (0.42) | CASRCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL6698536 | 0.87 | CASR (0.57) | CASR | |
| SCHEMBL4562924 | 0.87 | CASR (0.47) | CASR | |
| SCHEMBL4391778 | 0.86 | CASR (0.51) | CASRCCR5LMNA | |
| SCHEMBL4393814 | 0.86 | CASR (0.68) | CASRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4402008 | 0.85 | CASR (0.51) | CASRCCR5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | claimed |
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | CASR 2192/4885CCR5 433/4885ALDH1A1 3828/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | CASR 2483/4885CCR5 858/4885ALDH1A1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.